Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors
Open Access
- 8 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 12 (6), e11571
- https://doi.org/10.15252/emmm.201911571
Abstract
Small molecular PD-1 inhibitors are lacking in current immuno-oncology clinic. PD-1/PD-L1 antibody inhibitors currently approved for clinical usage block interaction between PD-L1 and PD-1 to enhance cytotoxicity of CD8(+) cytotoxic T lymphocyte (CTL). Whether other steps along the PD-1 signaling pathway can be targeted remains to be determined. Here, we report that methylene blue (MB), an FDA-approved chemical for treating methemoglobinemia, potently inhibits PD-1 signaling. MB enhances the cytotoxicity, activation, cell proliferation, and cytokine-secreting activity of CTL inhibited by PD-1. Mechanistically, MB blocks interaction between Y248-phosphorylated immunoreceptor tyrosine-based switch motif (ITSM) of human PD-1 and SHP2. MB enables activated CTL to shrink PD-L1 expressing tumor allografts and autochthonous lung cancers in a transgenic mouse model. MB also effectively counteracts the PD-1 signaling on human T cells isolated from peripheral blood of healthy donors. Thus, we identify an FDA-approved chemical capable of potently inhibiting the function of PD-1. Equally important, our work sheds light on a novel strategy to develop inhibitors targeting PD-1 signaling axis.This publication has 46 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2The Journal of Experimental Medicine, 2012
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- Fluorescence complementation: an emerging tool for biological researchTrends in Biotechnology, 2008
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesCancer Cell, 2006
- Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor SignalingMolecular and Cellular Biology, 2003
- Interleukin 2 and its receptors: recent advances and new immunological functionsImmunology Today, 1996
- Tumor necrosis factor‐α production induced in T lymphocytes through the AIM/CD69 activation pathwayEuropean Journal of Immunology, 1992
- A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activityJournal of Immunological Methods, 1988
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988